A Physician Was Just Indicted for Selling Imported Peptides to His Own Patients: What Med Spas and GLP-1 Clinics Need to Know

A federal grand jury has indicted a licensed physician for buying peptides from China through a middleman, relabeling the vials and pill bottles himself, and selling them to more than 200 of his own patients. This is not a paperwork violation. It is a federal felony.

If you run a med spa, a weight loss clinic, a compounding pharmacy, or a wellness practice, or you prescribe GLP-1 drugs like semaglutide and tirzepatide, this case matters to you. It shows the government has moved past shutting down websites. It is now charging the providers.

Key Takeaways

A licensed physician was indicted in the District of Utah for receiving misbranded, non-FDA-approved peptides from China and selling them to more than 200 patients.

The core charge runs under the Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 331 and 333, a felony of up to ten years per count when the government alleges intent to defraud or mislead.

Compounding defenses turn on 21 U.S.C. §§ 353a and 353b. When a clinic bills insurance, 18 U.S.C. § 1347 and 18 U.S.C. § 1343 stack on top.

FDA Office of Criminal Investigations builds these cases from import records, payment data, and the clinic's own marketing, often long before anyone is contacted.

South Florida and the Southern District of Florida are among the most active federal healthcare enforcement zones in the country, and med spas here carry real exposure.

The Utah indictment is the government's template for charging providers who source peptides outside authorized channels. The FDA investigates. The DOJ charges.

What the Indictment Actually Alleges

On April 1, 2026, a federal grand jury in Salt Lake City returned an eight-count indictment against a Utah osteopathic physician. According to the court record, between February 2024 and April 2025 he obtained peptides from China through a middleman, knowing they were not FDA approved. The list reads like a med spa menu: tirzepatide, semaglutide, retatrutide, cagrilintide, BPC-157, TB-500, ipamorelin, CJC-1295, and NAD+.

He bought them at deeply discounted prices, knew they were not backed by reliable testing or clinical trials, and made and affixed his own labels to the vials and bottles before handing them to clinic staff. None of those labels disclosed the manufacturer, packer, or distributor the way federal law requires. He then sold the products to more than 200 patients who trusted him.

That conduct is charged as receiving misbranded drugs in interstate commerce and delivering them for pay with intent to defraud or mislead, plus aiding and abetting under 18 U.S.C. § 2. The case was investigated by FDA Office of Criminal Investigations and a state professional licensing division, which is the pattern in nearly every peptide prosecution: a federal criminal track and a state license track moving at the same time.

What the Government Is Building, and Where

Peptide and GLP-1 cases rarely start with the FBI. They start with the FDA. An inspection or a complaint produces a finding, the finding becomes a warning letter, and the warning letter gets referred to FDA Office of Criminal Investigations, which brings in the Department of Justice. By the time a provider hears from an agent, the government already has import records, payment processor data, and years of marketing.

The supply side is under the same pressure. In one recent operation, Customs and Border Protection intercepted more than 300 cartons used to smuggle roughly 5,000 shipments of GLP-1 peptides, mislabeled to clear the border. The marketing side is also a target: the FDA sent a second round of warning letters to 30 telehealth companies over illegal claims about compounded GLP-1 products. In these cases, the advertising is the evidence.

The Florida picture is just as active. The FDA cited a Florida 503B outsourcing facility for repackaging retatrutide, semaglutide, and tirzepatide without approved applications, and for releasing a product contaminated with endotoxins that sent at least three patients to the emergency room. In Miami, a cosmetic injector was arrested mid-appointment and charged at the state level with practicing health care without a license and possessing an illegally imported alternative to Botox. Federal cases set the national tone. Florida state charges show how fast the same conduct gets prosecuted close to home.

None of this is new. The Department of Justice already forced a Kentucky compounder to forfeit $1.79 million for distributing unapproved peptides, including BPC-157. And the peptide reclassification that officials signaled for 2026 has not changed a single rule yet.

The Charges and the Real Exposure

The backbone is the Food, Drug, and Cosmetic Act. Selling or distributing a misbranded drug is generally a misdemeanor, but Section 333 turns it into a felony of up to ten years per count once the government alleges intent to defraud or mislead. Misbranded is broader than people expect. A label that hides who made or distributed the product, or that calls an injectable a research chemical while it is sold for human use, can be enough.

For pharmacies, the fight often runs through the compounding carve-outs in Sections 353a and 353b. Whether a drug was made for a specific patient, whether the ingredient was eligible, and whether a shortage exception applied are factual battles, not slogans. When a clinic bills insurance, the government adds healthcare fraud and wire fraud, each carrying up to twenty years per count, and money laundering follows the proceeds. Forfeiture, loss of a DEA registration, exclusion from federal health programs, and a state licensing action can all run at once.

The one thing the government must prove on the felony counts is intent. Buying cheap product from an unverified foreign source and relabeling it by hand is the kind of fact that makes intent easy to argue. A clinic that relied on counsel, a medical director, and a real compliance process is a very different case. That gap is where the defense lives.

The Mistakes That Turn an Investigation Into an Indictment

Talking to agents without counsel. FDA Office of Criminal Investigations agents are not stopping by to warn you. They are trained interviewers, and anything you say becomes evidence.

Destroying or altering records. Purchase records, supplier messages, and patient files must be preserved exactly as they are. Destruction creates an obstruction charge that is often easier to prove than the underlying offense.

Treating a warning letter as only a compliance issue. In this space, a warning letter is frequently the step before a criminal referral. Answering it alone can lock you into positions that limit your options later.

Waiting for charges before hiring a lawyer. The most valuable work in a federal case happens before an indictment, while the government is still deciding what to do.

How These Cases Are Actually Defended

Pre-indictment intervention is where peptide and med spa cases are won or lost. Federal investigation defense led by counsel can control what the government sees, narrow its theory, and in some cases resolve a matter civilly instead of criminally before any charge is filed. Once an indictment is returned, that flexibility is mostly gone.

On the merits, the compounding statutes provide genuine defenses when the facts support them. Intent can be attacked through good-faith reliance on lawyers, consultants, and a medical director, and through the absence of a clear regulatory line for years. The marketing the government leans on can be put in context. Because a licensing case and a criminal case usually move at the same time, they have to be defended together, since a statement in one can sink the other.

Why the Timing Is the Whole Ballgame

Charging decisions are fluid early. A target letter, a subpoena, an FDA inspection, or a knock from agents is the signal to act, not to wait. Once an indictment is filed, the office has committed publicly and the leverage shifts to the government.

The regulatory picture adds a trap. Officials have signaled that roughly 14 peptides may return to legal compounding in 2026, but until a formal rule is published and takes effect, the law has not changed. Operating today on the expectation of tomorrow's rule is a gamble with criminal stakes. In South Florida, where federal healthcare enforcement is among the most aggressive in the country, that is not a gamble worth taking.

Common Questions

Can a doctor really be charged criminally just for selling peptides?

Yes. The recent District of Utah indictment charges a licensed physician under the Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 331 and 333, for selling misbranded, non-FDA-approved peptides to his patients. With an allegation of intent to defraud or mislead, each count is a felony that can carry up to ten years. A medical license does not place a provider outside federal drug law.

Does a research use only label protect a med spa or vendor?

No. The FDA and the Department of Justice have rejected that label as a defense when the product is marketed or used for humans. What controls is how the product was actually sold and used. Selling an injectable for patient use while calling it a research chemical can itself support a misbranding charge under 21 U.S.C. § 331.

Are compounded semaglutide and tirzepatide still legal for my clinic?

The legal cover narrowed sharply once the FDA removed semaglutide and tirzepatide from the shortage list. Compounding now has to fit the carve-outs in 21 U.S.C. §§ 353a and 353b, which are technical and fact-specific. A clinic still sourcing or administering compounded GLP-1 drugs should have the arrangement reviewed before the FDA asks questions, not after.

The FDA sent my clinic a warning letter. Am I about to be indicted?

Not necessarily, but it should be taken seriously. In this area, warning letters are frequently the step before a referral to FDA Office of Criminal Investigations. Responding on your own can lock you into positions that limit your options later. This is the moment for federal investigation defense counsel, not a wait-and-see approach.

Why do peptide and med spa cases hit harder in Florida?

South Florida and the Southern District of Florida are among the most active federal healthcare enforcement regions in the country, with a dense market of med spas, clinics, and compounders. State authorities move quickly too, as recent Miami arrests show. The same conduct that draws a warning letter elsewhere can draw a faster, harder response here.

If you own or operate a med spa, clinic, pharmacy, or wellness business that has touched peptides, semaglutide, tirzepatide, or other GLP-1 products, and you have received a warning letter, a subpoena, or a visit from federal agents, the time to talk to a lawyer is before charges are filed. AMC Defense Law represents physicians, clinic and pharmacy owners, and wellness entrepreneurs in federal investigations nationwide and across South Florida. To discuss your situation confidentially with Aaron M. Cohen, contact AMC Defense Law.